Portal vein embolization before right hepatectomy: prospective clinical trial

OBJECTIVE: To assess the impact of liver hypertrophy of the future liver remnant volume (FLR) induced by preoperative portal vein embolization (PVE) on the immediate postoperative complications after a standardized major liver resection. SUMMARY BACKGROUND DATA: PVE is usually indicated when FLR is estimated to be too small for major liver resection. However, few data exist regarding the exact quantification of sufficient minimal functional hepatic volume required to avoid postoperative complications in both patients with or without chronic liver disease. METHODS: All consecutive patients in whom an elective right hepatectomy was feasible and who fulfilled the inclusion and exclusion criteria between 1998 and 2000 were assigned to have alternatively either immediate surgery or surgery after PVE. Among 55 patients (25 liver metastases, 2 cholangiocarcinoma, and 28 hepatocellular carcinoma), 28 underwent right hepatectomy after PVE and 27 underwent immediate surgery. Twenty-eight patients had chronic liver disease. FLR and estimated rate of functional future liver remnant (%FFLR) volumes were assessed by computed tomography. RESULTS: The mean increase of FLR and %FFLR 4 to 8 weeks after PVE were respectively 44 +/- 19% and 16 +/- 7% for patients with normal liver and 35 +/- 28% and 9 +/- 3% for those with chronic liver disease. All patients with normal liver and 86% with chronic liver disease experienced hypertrophy after PVE. The postoperative course of patients with normal liver who underwent PVE before right hepatectomy was similar to those with immediate surgery. In contrast, PVE in patients with chronic liver disease significantly decreased the incidence of postoperative complications as well as the intensive care unit stay and total hospital stay after right hepatectomy. CONCLUSIONS: Before elective right hepatectomy, the hypertrophy of FLR induced by PVE had no beneficial effect on the postoperative course in patients with normal liver. In contrast, in patients with chronic liver disease, the hypertrophy of the FLR induced by PVE decreased significantly the rate of postoperative complications.     

Preoperative portal vein embolization for hepatocellular carcinoma]

We performed preoperative portal vein embolization (PVE) for 71 patients with hepatocellular carcinoma (HCC), 59 of whom underwent hepatectomy about two weeks after PVE. The purpose of the PVE was usually to embolize the portal vein supplying the area to be resected. After PVE, the non-embolized part of the liver became hypertrophic and the embolized part of the liver became atrophic. Of the 22 patients who underwent right lobectomy after PVE of the right first branch of the portal vein, the mean results of a test of 15-minute indocyanine green retention after PVE increased significantly less than the mean for six patients who could not undergo right lobectomy after PVE of their right first branch. The extent of this increase and the liver volume of the left lobe 4 weeks after right lobectomy were higher in another 15 patients who did not undergo PVE than 22 patients who underwent PVE. PVE is useful as one preparation for hepatectomy of patients with HCC, because the embolized part of the liver was damaged by PVE, but mean liver function was compensated by the part of the liver that was not embolized and regenerated.     

术前门静脉栓塞术在肝门部胆管癌扩大肝切除术中的应用研究

目的 评价肝门部胆管癌扩大肝切除术前行门静脉栓塞术的有效性及安全性,比较门静脉栓塞手术切除术与非门静脉栓塞手术切除术后结果.方法 2007年5月至2010年10月收治肝门部胆管癌患者57例,分为两组,将预保留肝占全肝体积＜50％、术前接受门静脉栓塞(PVE)者设为PVE组(26例),男16例,女10例,年龄(56.48...     

Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers: A preliminary report

With the aim of minimizing postoperative liver dysfunction and promoting increased resectability, we employed portal vein embolization (PVE). In this study, the effect of PVE on major hepatic resection for advanced-stage hepatocellular carcinoma (HCC) in injured livers was evaluated. PVE was performed prior to hepatectomy in 13 patients with stage III and IV HCCs. Following PVE, right trisegmentectomy was performed in 3 patients, extended right lobectomy in 3 and right lobectomy in 7. To evaluate the effect of PVE, the changes in liver functional capacity and estimated remnant liver volume (ERLV), determined by computed tomography, were examined before and after PVE. The operative morbility, mortality, and survival rates after hepatectomy were also assessed. By 2 weeks after PVE, ERLV had increased in all patients, by an average of 28%, and the mean resection rates had decreased from 70.0% to 62.2%. Postoperatively, the 30-day mortality rate was 15.3%, and the 1- and 2-year survival rates were 69% and 46%, respectively. The results of this study indicate that resectability can be increased, and major hepatectomy can be made safer by employing PVE preoperatively, in view of the fact that major hepatectomy was not considered feasible without PVE in these patients.     

Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test.

BACKGROUND: Liver failure is the commonest cause of postoperative death in patients with hepatocellular carcinoma (HCC). With the improvement in operative technique and perioperative care, the limit of hepatic functional reserve may be lowered. The aim of this study was to evaluate the postoperative morbidity, mortality and survival rates in patients with an indocyanine green (ICG) retention value higher than 14 per cent, after major hepatectomy for HCC. METHODS: From January 1994 to December 1997, 117 patients underwent major hepatectomy for HCC; 92 patients had preoperative ICG retention at 15 min lower than 14 per cent (median 8.3 (range 1.6-13.8) per cent), while 25 patients had ICG retention greater than 14 per cent (17.4 (range 14.3-35.3) per cent). Data were collected prospectively and analysed retrospectively. RESULTS: The two groups of patients were similar in terms of age, sex ratio, preoperative platelet count, liver biochemistry, Child-Pugh status and operative procedures performed, but the prothrombin time was significantly longer in the high ICG group. The operative blood loss (1.5 litres), the amount of blood transfused and the number of patients requiring blood transfusion were similar. The postoperative complication rate (41 versus 40 per cent), duration of hospital stay (12 versus 13 days), hospital mortality rate (1 versus 4 per cent) and median survival time (47 versus 45 months) were not significantly different. CONCLUSION: With meticulous surgical technique to decrease intraoperative blood loss and good perioperative care, selected patients with limited hepatic functional reserve can achieve a good immediate postoperative result and a survival rate similar to that of patients with good hepatic functional reserve.     

Dynamics of portal and peripheral endothelin-1 in hepatic resection and its implication.

BACKGROUND: The liver and portal circulation contribute to production and clearance of endothelin-1 (ET-1). This study was undertaken to investigate what variables relate to the dynamics of ET-1 in hepatic resection and its clinical implication. PATIENTS AND METHODS: On 20 patients with (n = 8) or without (n = 12) chronic liver disease who underwent hepatic resection, peripheral arterial and portal venous ET-1 were serially measured to determine a correlation with pre-, intra-, and postoperative variables. RESULTS: The preoperative factors with which the portal ET-1 showed a positive correlation were the indocyanine green retention rate at 15 min (ICG R15) and portal venous pressure. The ET-1 clearance, as calculated from the difference between the portal and the peripheral ET-1 concentrations, was also correlated with the ICG R15. The peripheral ET-1 elevated significantly in the patients with increasing intraoperative blood loss or hepatic inflow occlusion. An increase in the portal ET-1 was correlated with an elevation of portal venous pressure after hepatectomy. Postoperative increase in serum bilirubin was closely correlated with the peripheral ET-1 at closure. CONCLUSION: The peripheral and portal ET-1 are correlated with not only preoperative hepatic reserve and portal venous pressure but also invasiveness of hepatectomy and postoperative course.     

Parameters associated with changes in liver volume in patients undergoing portal vein embolization

BACKGROUND: To identify predictors of changes in hepatic volumes after portal vein embolization (PVE) before hepatectomy, we examined the relationship between clinicopathological parameters and changes in volume of embolized and nonembolized liver and regeneration of remnant liver after hepatectomy. MATERIALS AND METHODS: The subjects were 25 patients who underwent laparotomy. PVE was performed through transileocolic vein (n = 15) and percutaneous transhepatic puncture (n = 10). RESULTS: Significant atrophy and hypertrophy of the embolized and nonembolized liver were observed after PVE, respectively, and further increase of remnant liver volume was observed after hepatectomy. Background liver disease did not seem to influence the results. Alkaline phosphatase (ALP) level correlated negatively with atrophy of embolized lobe (r = -0.433). Platelet count correlated positively with hypertrophy of nonembolized lobe (r = 0.412, P < 0.05) and percent increase between lobes and (r = 0.515, P < 0.05). Seven (32%) patients developed postoperative complications, such as long-term ascites or cholestasis. Changes in embolized liver and percent increase between lobes in patients with postoperative cholestasis (-94 +/- 97 cm(3) and 9.6 +/- 5.1% gain) were significantly lower than those in patients without cholestasis (17 +/- 54 cm(3) and 6.6 +/- 1.3% gain, P < 0.05). CONCLUSION: ALP and platelet counts might be able to predict PVE effect and were related to postoperative course. Identification of more specific predictors is desirable.     

肝门部胆管癌术前行门静脉栓塞16例分析

目的 探讨未来残余肝较小的肝门部胆管癌病人行门静脉栓塞是否安全有效。 方法 对2007年1月至2009年3月第二军医大学附属东方肝胆外科医院拟行大部肝切除、未来残余肝/全肝体积（FLR/ TLV）比<50%的16例接受钢圈门静脉栓塞（portal vein embolization,PVE）的临床资料进行分析。 结果 术前16例（PVE组）因肝功能损害、FLR/TLV < 50%者行PVE治疗,33例（非PVE组）FLR/TLV > 50%者行肿瘤联合肝切除。PVE后3例出现并发症,原因为胆漏和钢圈移位,但未推迟肝切除术日期。16例PVE中1例合并肝硬化出现非栓塞肝叶增生不全而未能接受外科治疗,2例术中发现肿瘤进展、腹膜播散未能接受肝切除术,余13例（81.3%）行联合肝切除的肿瘤切除术。PVE组和非PVE组的手术并发症发生率分别为69.2%及63.6%,手术死亡率为0及9.1%。二者相比差异无统计学意义。结论 PVE能安全、有效地诱导肝门胆管癌术前未来残余肝增生。     

门静脉栓塞术在肝脏肿瘤二期切除中的应用

目的 探讨门静脉栓塞术在肝脏肿瘤二期切除过程中的作用与安全性。方法 分析总结5例难以一期切除肝脏肿瘤,先行门静脉栓塞术后再行二期肿瘤切除患者的临床资料。所有患者均采用B超及DSA引导下经皮肝门静脉左支穿刺法对门静脉右支进行栓塞。检测门静脉栓塞术后肝功能及肝叶体积变化,总结门静脉栓塞与肿瘤二期切除手术成功率。结果 5例患者均成功实施PVE术,术后出现一过性的肝功能减退,经保肝治疗短期恢复,未栓塞侧肝脏体积代偿性增大明显,达到预期效果;所有病例均顺利完成二期肝叶切除术,术后肝功能良好。结论 门静脉栓塞术成功率高、安全可行,对侧肝脏代偿性增大明显,达到预期目的,使得难以一期切除的肝脏肿瘤可以切除,从而提高肝脏肿瘤的切除率。     

余肝不足肝癌手术治疗争议与共识

手术切除是肝癌病人获得长期生存的主要治疗方式。近年来肝脏外科进展迅速,手术适应证不断扩大。肝脏解剖复杂性和手术操作已不再是肝脏外科发展的障碍,剩余肝足够与否成为限制肝脏手术的瓶颈。目前,人工肝支持技术尚不成熟,余肝不足肝癌手术的主要策略是诱导余肝增生然后再切除肿瘤的二步切除法,以及针对原发或转移性肿瘤的降期或转化治疗。二步切除的主要方法目前仍为门静脉栓塞（PVE）或门静脉结扎（PVL）的二步肝切除术。对于肝细胞肝癌,联合肝动脉化疗栓塞可进一步改善治疗效果。近年来,联合肝脏分隔和门静脉结扎的二步肝切除术（ALPPS）的出现为余肝不足的肝癌手术带来新的突破。该方法可在短时间内诱导显著的肝脏增生,但是术后并发症发生率和手术死亡率较高,在手术安全性及肿瘤转归方面尚有争议。近年来原发或转移性肝癌的降期或转化治疗伴随着非手术技术的进步,亦有很大进展,已使越来越多的病人能够手术获益。     

Prediction of postoperative hepatic dysfunction after cardiac surgery in patients with chronic congestive heart failure

Objective  Chronic congestive liver dysfunction in advanced valvular disease remains an important co-morbidity in open heart surgery. The objective of this study was to explore the prognostic value in patients with severe valvular disease associated with congestive liver dysfunction. Methods  From 1997 to 2004, a total of 63 patients who had valvular disease with moderate or severe tricuspid regurgitation were studied. In addition to the indocyanine green retention rate at 15 min (ICG15) and the Child-Pugh score, we measured serum total bilirubin (T-bil), asparate aminotransferase (AST), alanine aminotransferase (ALT), cholinesterase (ChE), albumin (Alb) concentration, and prothrombin time. We compared these preoperative factors with postoperative liver dysfunction and mortality and attempted to develop a new liver function score. Results  There were eight in-hospital deaths (13%). Seventeen patients had postoperative liver dysfunction. The univariate analysis indicated there were significant differences in preoperative T-bil, Alb, ChE, ICG15, and Child-Pugh score between the patients with and without liver dysfunction. Multivariate logistic regression analysis also identified preoperative T-bil as a significant indicator of postoperative liver dysfunction and preoperative ChE as a predictor of mortality. Based on these findings, we introduced a liver function score to predict postoperative dysfunction and death. Conclusion  In addition to preoperative ChE, T-bil and Alb appeared to be valuable for producing obtainable prognostic information regarding postoperative liver dysfunction in patients with severe valvular disease. A new liver score, including T-bil, ChE, and Alb, is proposed for predicting postoperative hepatic dysfunction and outcome.     

肝静脉-门静脉联合栓塞术促进预留肝脏快速增生——结直肠癌肝转移转化切除新策略

目的 评价肝静脉-门静脉联合栓塞术（HVE+PVE）安全性、促进预留肝脏增生的能力及联合系统治疗用于初始不可切除结直肠癌肝转移（CRLM）转化切除的可行性。方法 回顾性分析2020年12月至2021年11月复旦大学附属中山医院3例肝左、右叶多发初始不可切除CRLM病例经系统治疗后,病灶缩小,但剩余肝体积（FLR）不足,行HVE+PVE后转化切除的临床资料。结果 HVE+PVE后平均18.6 d,FLR从平均423.6 mL增生至561 mL,平均增长率32.8%;剩余肝体积（FLR）/标准肝体积（SLV）从平均33.5%增至43.8%,无并发症发生。HVE+PVE后平均23 d行右半肝+左肝部分切除术等,平均出血333.3 mL,未输血。术后无Clavien-Dindo Ⅲ级以上并发症,无肝功能衰竭及90 d死亡。均获得R0切除。平均11.3 d出院。结论 HVE+PVE通过介入操作即可使FLR快速增生,具有操作简捷、创伤小、安全等优点。联合系统治疗可以增加初始不可切除CRLM的转化切除率。     

ICG Clearance in Assessing Cirrhotic Patients with Hepatocellular Carcinoma for Major Hepatic Resection

Objective: To deWne the safety of major hepatectomy for hepatocellular carcinoma (HCC) associated with cirrhosis and the selection criteria for surgery in terms of hospital mortality. Design: Major hepatectomy for HCC in the presence of cirrhosis is considered to be contraindicated by many surgeons because the reported mortality rate is high (26% to 50%). Previous workers recommended that only selected patients with Child''s A status or indocyanine green (ICG) retention at 15 minutes of less than 10% undergo major hepatectomy. A survery was made, therefore, of our patients with HCC and cirrhosis undergoing major hepatectomy between 1989 and 1994. Setting: A tertiary referral center. Patients: The preoperative, intraoperative, and post-operative data of 54 patients with cirrhosis who had major hepatectomy were compared with those of 25 patients with underlying chronic active hepatitis and 22 patients with normal livers undergoing major hepatectomy for HCC. The data had been prospectively collected. Intervention: Major hepatectomy, defined as resection of two or more liver segments by Goldsmith and Woodburn nomenclature, was performed on all the patients. Main Outcome Measure: Hospital mortality, which was defined as death within the same hospital admission for the hepatectomy. Results: Preoperative liver function in patients with cirrhosis was worse than in those with normal livers. The intraoperative blood loss was also higher (P=.01), but for patients with cirrhosis, chronic active hepatitis, and normal livers, the hospital mortality rates (13%, 16%, and 14%, respectively) were similar. The hospital mortality rate for patients with cirrhosis in the last 2 years of the study was only 5%. Patients with cirrhosis could tolerate up to 10 L of blood loss and survive the major hepatectomy. By discriminant analysis, an ICG retention of 14% at 15 minutes was cutoff level that could maximally separate the patients with cirrhosis with and without mortality. Conclusion: Major hepatectomy for HCC in the presence of cirrhosis is associated with a mortality rate that is not different from the rate for patients with normal livers. An ICG retention of 14% at 15 minutes would serve as a better selection criterion than the 10% previously used.     

Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma

HYPOTHESIS: Hepatic resection is the only curative treatment for large hepatocellular carcinoma (HCC). Sequential, preoperative, selective transcatheter arterial chemoembolization (TACE) and portal vein embolization (PVE) allow feasible and safe major hepatic resections to be performed in HCC patients with chronic liver disease. DESIGN: Retrospective cohort study. SETTING: University hospital. PATIENTS: Seventeen HCC patients who underwent preoperative PVE following selective TACE for planned major hepatic resections were enrolled. The indications for PVE were determined using the volumetric ratio of the future remnant liver parenchyma and the indocyanine green retention ratio at 15 minutes. INTERVENTION: Preoperative TACE and PVE. MAIN OUTCOME MEASURES: Tumor characteristics and blood test results before and after TACE and PVE, changes in the volumes of the liver segments after PVE, the feasibility of major hepatic resections, and short- and long-term patient prognoses. RESULTS: The liver function test results transiently worsened after TACE and PVE but returned to baseline levels within 1 (after TACE) or 2 (after PVE) weeks. Within 2 weeks after PVE, 22% +/- 4% hypertrophy of the nonembolized segments was obtained; subsequent major hepatic resections were feasible in 16 patients. Four minor complications (25%) were experienced postoperatively; however, liver failure did not occur. The 5-year overall and disease-free survival rates after curative resection were 55.6% and 46.7%, respectively. CONCLUSIONS: Sequential TACE and PVE contribute to both the broadening of surgical indications and the safety of major hepatic resections performed in HCC patients with damaged livers. The long-term outcome of this treatment strategy is satisfactory.     

Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver

OBJECTIVE: To assess the influence of preoperative portal vein embolization (PVE) on the long-term outcome of liver resection for hepatocellular carcinoma (HCC) in injured liver. SUMMARY BACKGROUND DATA: On an healthy liver, PVE of the liver to be resected induces hypertrophy of the remnant liver and increases the safety of hepatectomy. On injured liver, this effect is still debated. METHODS: During the study period, 10 patients underwent preoperative PVE and 19 patients did not before resection of three or more liver segments for HCC in injured liver (cirrhosis or fibrosis). PVE was performed when the estimated rate of remnant functional liver parenchyma (ERRFLP) assessed by computed tomographic scan volumetry was less than 40%. RESULTS: In all patients, PVE was feasible. There were no deaths or complications. The ERRFLP after PVE was significantly increased compared with the pre-PVE value. Liver resection was performed after PVE in 9 of 10 patients, with surgical death and complication rates of 0% and 45%, respectively. PVE increased the number of resections of three or more segments by 47% (9/19). Overall actuarial survival rates with or without previous PVE (89%, 67%, and 44% vs. 80%, 53%, and 53% at 1, 3 and 5 years, respectively) and disease-free actuarial survival rates (86%, 64%, and 21% vs. 55%, 17%, and 17% at 1, 3, and 5 years respectively) after hepatectomy were comparable. CONCLUSION: With the use of PVE, more patients with previously unresectable HCC in injured liver can benefit from resection. Long-term survival rates are comparable to those after resection without PVE.     

吲哚菁绿荧光实时成像技术在机器人肝切除中的初步应用(附二例报告)

目的探讨吲哚菁绿荧光实时成像技术在机器人辅助腹腔镜肝切除中应用的可行性。方法回顾性分析华中科技大学同济医学院附属同济医院2017年8月使用吲哚菁绿荧光实时成像技术行机器人肝切除的2例病人的临床资料。病例1原发性肝癌拟行机器人辅助腹腔镜肝8段切除,术前超声引导下经皮肝穿刺肝8段门静脉分支,注射吲哚菁绿染色剂;术中利用PINPOINT荧光显象系统确定切除边界并引导离断肝实质。病例2肝右叶海绵状血管瘤,术中经门静脉注入吲哚菁绿染色剂,对血管瘤进行负染,确定血管瘤边界,引导离断肝脏实质。结果病例1肝脏8段包膜及肝实质在PINPOINT系统中均呈现绿色荧光,与周围肝组织界限清晰,离断肝实质过程中可根据荧光指引肝切除平面,完整切除肝脏8段。病例2肝血管瘤无荧光染料滞留,与周围呈绿色荧光的肝组织界限清晰,在荧光指引下准确找到血管瘤包膜,并完整剜除。上述病人术中无大出血,术后恢复顺利,无并发症发生。结论吲哚菁绿荧光实时成像系统应用于机器人辅助腹腔镜肝切除手术是安全有效的。     

经皮微波或射频消融肝实质分隔联合门静脉栓塞计划性肝切除术治疗余肝体积不足肝癌及胆管癌3例报告

目的 探讨经皮微波或射频消融肝实质分隔联合门静脉栓塞计划性肝切除术（percutaneous microwave/radiofrequency ablation liver partition and portal vein embolization for planned hepatectomy,PAPEP）替代联合肝脏分隔和门静脉结扎的二步肝切除术（associating liver partition and portal vein ligation for staged hepatectomy, ALPPS）治疗剩余肝体积（future liver remnant,FLR）不足肝癌和胆管癌的可行性和安全性。方法 回顾性分析2015年7-9月浙江省人民医院肝胆胰外科应用PAPEP治疗FLR不足的2例原发性肝癌和1例肝门部胆管癌的临床资料。先超声引导下经皮微波消融分隔预留侧和切除侧肝实质（percutaneous microwave ablation liver partition,PMA）,PMA后1~3 d行门静脉栓塞术（portal vein embolization,PVE）,PVE后10~13 d测量FLR,术前系统评估后限期肝切除术：2例肝癌分别行肝右三叶和右尾叶切除术、扩大右半肝切除术,1例肝门部胆管癌行肝右三叶和尾叶切除、肝肠内引流术。结果 PMA前3例标准全肝体积（standard liver volume,SLV）分别为1231.2mL、1202.9mL、1217.1mL,FLR分别为355.6 mL、383.4 mL、385.0 mL,FLR/SLV分别为28.9%、31.9%、31.6%。PMA时间118~132 min, PVE时间158~180 min,PMA或PVE术后病人低热经对症处理好转,肝功能无明显变化。PMA+PVE后10~13 d FLR分别为502.1 mL、527.4 mL、476.3 mL,较术前分别增大41.2%、37.6%、23.7%。肝切除术时间230~440 min,术中出血120~1800 mL。肝门部胆管癌术后并发膈下脓肿,经穿刺后治愈;1例肝癌术后并发腹水、黄疸,经内科治疗后治愈,术后住院时间15~40 d。 结论 PAPEP有望代替ALPPS治疗剩余肝体积不足的肝癌或肝门部胆管癌。     

Resection for multiple metastatic liver tumors after preoperative portal embolization

Surgical resection has been recognized as the most effective treatment for patients with colorectal liver metastases. However, hepatectomy can be performed in only approximately 10% to 20%. Among the factors that are contraindications for hepatectomy, insufficient functional volume of the remnant liver after hepatic resection can cause postoperative hepatic failure and is still an obstacle to major hepatic resection. As one of the solutions to this dilemma and to be able to expand the indications for major hepatectomy, preoperative portal embolization (PVE) was proposed to induce compensatory hypertrophy of the contralateral remnant liver in patients with metastatic disease as well as in those with injured hepatic parenchyma, i.e., hepatocellular carcinoma and hilar cholangiocarcinoma. Currently, PVE allows more patients with previously unresectable liver tumors to benefit from resection. Long-term survival is comparable to that after resection without PVE.     

从ALPPS术式演变看肝癌外科治疗理念变迁

目前,手术仍是根治性治疗肝癌的最佳手段,但多数肝癌病人在较晚期方获得诊治,失去了外科手术切除的机会。近年来,关于如何提高手术切除率的研究层出不穷,联合肝脏分隔和门静脉结扎的二步肝切除术（associating liver partition with portal vein ligation for staged hepatectomy,ALPPS）的出现引起众多关注。ALPPS能快速诱导非肝癌肝组织的增生、提高手术切除率。与目前常用的门静脉栓塞（preoperative portal vein embolization,PVE）或术中门静脉结扎（portal vein ligation,PVL）联合肝切除术相比,ALPPS两步手术完成肝脏肿瘤切除时间明显缩短,且第2阶段肝切除术的切除率明显高于PVE或PVL联合肝切除术。尽管ALPPS的手术效果令人鼓舞,但病人围手术期病死率和并发症发生率仍然较高,限制了其广泛应用。     

ICGR15联合PT及标准残肝体积预测肝癌患者术后肝功能恢复

目的 探讨术前吲哚氰绿15分钟滞留率（indocyanine green retention rate at 15min,ICGR15）联合术前凝血酶原时间（prothrombin time,PT）及标准残肝体积（standard remnant liver volume,SRLV）对预测肝癌患者术后肝功能代偿的作用.方法 对64例因大肝癌行肝切除术的患者进行研究,根据术后患者肝功能代偿情况分组,对术前生化检查及一般情况进行差异性分析.结果 轻度肝功能代偿不全组（50例）、中重度肝功能代偿不全组（14例）之间ICGR15、PT、SRLV有统计学意义（P＜0.05）;Logistic回归分析得到回归方程为：PLFPI =0.186 × ICGR15 ＋0.849×PT-0.007×SRLV-9.617.经过ROC分析PLFPI预测术后肝功能重度代偿不全的临界值为-0.33,其灵敏度为100％,特异度为87.10％.结论 术前ICGR15联合术前PT及标准残肝体积能够较好地预测肝癌患者术后肝功能代偿情况;以PLFPI＜-33作为预防大肝癌肝切除术后重度肝功能代偿不全的术后肝功能综合预测指数界限是可行的.